Indivior PLC (LON:INDV – Get Free Report) traded up 8.1% during trading on Thursday . The company traded as high as GBX 848 ($10.86) and last traded at GBX 843 ($10.80). 1,729,744 shares traded hands during mid-day trading, an increase of 223% from the average session volume of 534,858 shares. The stock had previously closed at GBX 780 ($9.99).
Analysts Set New Price Targets
Separately, Deutsche Bank Aktiengesellschaft cut their price target on Indivior from GBX 2,350 ($30.10) to GBX 1,500 ($19.21) and set a “buy” rating for the company in a research note on Tuesday.
Read Our Latest Report on INDV
Indivior Trading Up 8.1 %
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Stories
- Five stocks we like better than Indivior
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Sales Breakout Sends This Semiconductor Stock to Record High
- 3 Warren Buffett Stocks to Buy Now
- Surprise Buying Opportunity on This Dividend Aristocrat
- How to Use the MarketBeat Stock Screener
- New Theme Park Powerhouse: Merger Creates Industry-Leading Stock
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.